Akèy › Sendwòm myelodisplastik › Utah
Etid klinik pou Sendwòm myelodisplastik nan Utah
8 etid pou Sendwòm myelodisplastik ap chèche patisipan nan sit nan Utah.
Vil nan Utah
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07422480The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Primary Children's Hospital, Salt Lake City
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT05308264Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT05297734A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.